An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy - Top-Institutions - MDSpire

An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy

  • By

  • Yunuo Zhao

  • Yuchi Zou

  • Shengxin Zhang

  • Yu Zhang

  • Xueyan Zhou

  • Shen Li

  • Yuwen Zhou

  • May 20, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    West China Hospital
    West China Hospital

    Chengdu, Sichuan

    Key Differentiators

    • Oncology

  • #2

    North Estonia Medical Centre (NEMC) Foundation
    North Estonia Medical Centre (NEMC) Foundation

    Tallinn, Harju

    Key Differentiators

    • Oncology

  • #3

    Stanford NSCLC Radiogenomics
    Stanford NSCLC Radiogenomics

    Stanford, California

    Key Differentiators

    • Oncology

  • #4

    The First Affiliated Hospital of Jinan University
    The First Affiliated Hospital of Jinan University

    Jinan, Shandong

    Key Differentiators

    • Oncology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

Original Source(s)

An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy

  • by Yunuo Zhao, Yuchi Zou, Shengxin Zhang, Yu Zhang, Xueyan Zhou, Shen Li, Yuwen Zhou

  • May 20, 2026

Related Content

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities